Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...
Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...
BerGenBio (OSE:BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.
Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) is developing breakthrough ultra-high-resolution, real-time, advanced imaging tools to assist cancer surgeons in achieving clean margins during initial surgery.
Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat cancer, improving...
Closely held Vizgen is pioneering next-generation genomics and benchmarking the spatial genomics field with its commercial MERSCOPE Platform, the industry’s first high plex in situ single-cell spatial genomics solution...
TriSalus Life Sciences (NASDAQ:TLSI) is addressing the mechanical and biologic barriers within the tumor microenvironment (TME) that make it challenging to successfully treat liver and pancreatic tumors.
Closely-held xNARA Biologics is reshaping the wellness industry through personalized health and wellness solutions designed to address genetic predispositions and disorders identified by analyzing individual DNA, gut...
Closely held Simtra BioPharma Solutions, a premier contract development and manufacturing organization with more than 65 years of sterile injectable manufacturing experience, offers world-class cGMP sterile fill/finish...
As founder and executive chair of the non-profit Indo-US Organization for Rare Disease (IndoUSrare), Harsha Rajasimha, Ph.D., social entrepreneur, and subject matter expert in bioinformatics, data analysis, and...
Personalis (NASDAQ:PSNL) is developing a liquid biopsy assay designed to detect minimal residual disease (MRD) and cancer recurrence earlier than other diagnostic methods.
Gritstone bio (NASDAQ:GRTS) is expecting in the first quarter of 2024 preliminary data from its Phase 2/3 study evaluating the Company's personalized neoantigen vaccine candidate for the treatment of colorectal cancer...
Closely held Upswing Health, a virtual orthopedic company, is reinventing orthopedic care delivery through its virtual orthopedic musculoskeletal symptom assessment tool and customized pain management program...
Closely held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.
Closely held Rainhouse Manufacturing, a company specializing in computer numerical control (CNC) machining, quality assurance, and electronic manufacturing, is working with companies to make their medical device designs...
Closely held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which...
Closely held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...
Closely held EndoGlow, a medical device company, is revolutionizing minimally invasive surgery and improving patient outcomes by enhancing visualization through its proprietary Tissue Reveal Technology (TRT), a polymer...
Closely held Inbound Health is enabling its health system partners to provide hospital and skilled nursing facility (SNF)-level care to patients in the comfort of their own home.
Korro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s...
MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...
Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...